• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性阻塞性肺疾病患者的治疗持久性和依从性:多种长效维持吸入器与单一长效维持吸入器。

Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers.

机构信息

Analysis Group Inc., Boston, MA, USA.

出版信息

J Med Econ. 2011;14(4):486-96. doi: 10.3111/13696998.2011.594123. Epub 2011 Jun 16.

DOI:10.3111/13696998.2011.594123
PMID:21679019
Abstract

OBJECTIVE

To compare persistence and adherence among patients with chronic obstructive pulmonary disease (COPD) treated with either multiple- or single- long-acting maintenance inhalers.

METHODS

Patients with ≥2 COPD medical claims and ≥2 prescriptions for a long-acting inhaler within 1 year were classified as single- or multiple-inhaler users based on their treatment regimen (MarketScan database; 2004-2008) and matched on demographics and statistically significant baseline characteristics. Persistence, analyzed via time to treatment discontinuation, and treatment adherence, measured by proportion of days covered (PDC), were compared between the two groups over a 12-month period. Sensitivity analyses were conducted in patients with poorly and well-controlled disease.

RESULTS

A total of 23,494 patients were grouped into 11,747 matched pairs. After adjusting for confounding factors, multiple-inhaler users had a significantly higher discontinuation rate [Hazard ratio = 1.40, p < 0.0001] compared with single-inhaler users. Multiple-inhaler users were less likely to be adherent than single-inhaler users with an average PDC of 0.51 (SD = 0.272) vs. 0.55 (SD = 0.279), respectively (p < 0.0001). These results were consistent for the poorly- and well-controlled disease groups.

CONCLUSIONS

Multiple long-acting inhaler users demonstrated lower treatment persistence and adherence rates than single long-acting inhaler users. Limitations of the study are related to the retrospective, observational design and use of claims data.

摘要

目的

比较慢性阻塞性肺疾病(COPD)患者使用多种或单一长效维持吸入器的持续性和依从性。

方法

根据治疗方案(MarketScan 数据库;2004-2008 年),将一年内至少有 2 次 COPD 医疗索赔和至少有 2 次长效吸入器处方的患者分为单一或多种吸入器使用者,并根据人口统计学和具有统计学意义的基线特征进行匹配。在 12 个月期间,通过治疗中断时间分析比较两组患者的持续性,通过覆盖天数比例(PDC)测量治疗依从性。在疾病控制不佳和控制良好的患者中进行了敏感性分析。

结果

共纳入 23494 例患者,分为 11747 对匹配患者。调整混杂因素后,与单一吸入器使用者相比,多吸入器使用者的停药率显著升高[风险比=1.40,p<0.0001]。与单一吸入器使用者相比,多吸入器使用者的依从性较低,平均 PDC 分别为 0.51(SD=0.272)和 0.55(SD=0.279)(p<0.0001)。这些结果在疾病控制不佳和控制良好的组中是一致的。

结论

与单一长效吸入器使用者相比,多种长效吸入器使用者的治疗持续性和依从性较低。研究的局限性与回顾性、观察性设计和索赔数据的使用有关。

相似文献

1
Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers.慢性阻塞性肺疾病患者的治疗持久性和依从性:多种长效维持吸入器与单一长效维持吸入器。
J Med Econ. 2011;14(4):486-96. doi: 10.3111/13696998.2011.594123. Epub 2011 Jun 16.
2
Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD.COPD 中多种长效吸入器与单一长效吸入器的临床和经济结局。
Respir Med. 2011 Dec;105(12):1861-71. doi: 10.1016/j.rmed.2011.07.001. Epub 2011 Jul 31.
3
Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies.与其他控制疗法相比,使用氟替卡松丙酸酯和沙美特罗单一吸入器可提高药物续方依从性。
J Allergy Clin Immunol. 2004 Feb;113(2):245-51. doi: 10.1016/j.jaci.2003.10.011.
4
Association of chronic obstructive pulmonary disease maintenance medication adherence with all-cause hospitalization and spending in a Medicare population.慢性阻塞性肺疾病维持药物依从性与医疗保险人群全因住院及费用的关联
Am J Geriatr Pharmacother. 2012 Jun;10(3):201-10. doi: 10.1016/j.amjopharm.2012.04.002. Epub 2012 Apr 21.
5
Inhaler mishandling is very common in patients with chronic airflow obstruction and long-term home nebuliser use.在慢性气流阻塞患者和长期家庭雾化器使用患者中,吸入器使用不当非常常见。
Respir Med. 2012 May;106(5):668-76. doi: 10.1016/j.rmed.2011.11.016. Epub 2012 Jan 25.
6
Delivery of ipratropium and albuterol combination therapy for chronic obstructive pulmonary disease: effectiveness of a two-in-one inhaler versus separate inhalers.异丙托溴铵和沙丁胺醇联合治疗慢性阻塞性肺疾病:二合一吸入器与单独吸入器的疗效比较
Am J Manag Care. 2002 Oct;8(10):902-11.
7
The importance of inhaler devices: the choice of inhaler device may lead to suboptimal adherence in COPD patients.吸入装置的重要性:吸入装置的选择可能导致慢性阻塞性肺疾病(COPD)患者的依从性欠佳。
Int J Chron Obstruct Pulmon Dis. 2015 Oct 29;10:2335-45. doi: 10.2147/COPD.S90155. eCollection 2015.
8
Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD.对于患有稳定的中重度慢性阻塞性肺疾病(COPD)的成年受试者,使用压力定量吸入器(pMDI)和储雾罐给药的噻托溴铵产生的支气管扩张反应与使用旋转式吸入器给药的相似。
Respir Med. 2007 Dec;101(12):2464-71. doi: 10.1016/j.rmed.2007.07.006. Epub 2007 Aug 24.
9
Effects of inhaled corticosteroids in monotherapy or combined with long-acting {beta}2-agonists on mortality among patients with chronic obstructive pulmonary disease.吸入性皮质类固醇单药治疗或与长效β2-激动剂联合治疗对慢性阻塞性肺疾病患者死亡率的影响。
Ann Pharmacother. 2010 Apr;44(4):613-22. doi: 10.1345/aph.1M243. Epub 2010 Mar 16.
10
Enhanced persistence with tiotropium compared with other respiratory drugs in COPD.与其他用于慢性阻塞性肺疾病(COPD)的呼吸药物相比,噻托溴铵的作用持续时间更长。
Respir Med. 2007 Jul;101(7):1398-405. doi: 10.1016/j.rmed.2007.01.025. Epub 2007 Mar 23.

引用本文的文献

1
Inhaler identification: evaluating a potential screening method for adherence in chronic respiratory disease management.吸入器识别:评估一种用于慢性呼吸道疾病管理中依从性的潜在筛查方法。
J Bras Pneumol. 2025 Sep 8;51(3):e20250393. doi: 10.36416/1806-3756/e20250393. eCollection 2025.
2
Economic Analysis of New Single-Inhaler Triple Therapies in Patients with COPD in the UK.英国慢性阻塞性肺疾病患者新型单吸入器三联疗法的经济学分析
Int J Chron Obstruct Pulmon Dis. 2025 Aug 7;20:2727-2743. doi: 10.2147/COPD.S475748. eCollection 2025.
3
Treatment Patterns and Triple Therapy Utilization in Chinese Patients with Chronic Obstructive Pulmonary Disease: An Analysis of Real-World Data from the Yinzhou Database.
中国慢性阻塞性肺疾病患者的治疗模式与三联疗法应用:基于鄞州数据库真实世界数据的分析
Int J Chron Obstruct Pulmon Dis. 2025 Jul 29;20:2659-2670. doi: 10.2147/COPD.S499783. eCollection 2025.
4
Real-World Effectiveness of Single-Inhaler Triple Treatment Through Assorted Respiratory Outcomes When Switched From Multiple-Inhaler Triple Therapies (RESTART): A Prospective Cohort Study of Korean Patients With COPD.从多吸入器三联疗法转换为单吸入器三联疗法后的多种呼吸结局的真实世界有效性(重启):一项针对韩国慢性阻塞性肺疾病患者的前瞻性队列研究
Int J Chron Obstruct Pulmon Dis. 2025 Apr 11;20:1039-1050. doi: 10.2147/COPD.S499686. eCollection 2025.
5
Effectiveness of Switching from Multiple-Inhaler to Once-Daily Single-Inhaler Triple Therapy in Patients with COPD in a Real-World Setting in Japan.在日本真实世界环境中,慢性阻塞性肺疾病(COPD)患者从多吸入器治疗转换为每日一次单吸入器三联疗法的有效性。
Int J Chron Obstruct Pulmon Dis. 2025 Mar 8;20:565-580. doi: 10.2147/COPD.S478455. eCollection 2025.
6
Comparative Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol and Budesonide/Glycopyrrolate/Formoterol Fumarate among US Patients with Chronic Obstructive Pulmonary Disease.糠酸氟替卡松/乌美溴铵/维兰特罗与布地奈德/格隆溴铵/富马酸福莫特罗在美国慢性阻塞性肺疾病患者中的疗效比较
Adv Ther. 2025 Feb;42(2):1131-1146. doi: 10.1007/s12325-024-03088-1. Epub 2024 Dec 28.
7
Comparative adherence and persistence of single-inhaler and multiple-inhaler triple therapies among patients with chronic obstructive pulmonary disease in Japan: a retrospective cohort study.日本慢性阻塞性肺疾病患者中单一吸入器与多吸入器三联疗法的依从性和持续性比较:一项回顾性队列研究
BMJ Open. 2024 Dec 4;14(12):e080864. doi: 10.1136/bmjopen-2023-080864.
8
Evaluation of Adherence and Persistence to Triple Therapy in Patients with COPD: A German Claims Data Study.评价 COPD 患者三联疗法的依从性和持久性:一项德国索赔数据研究。
Int J Chron Obstruct Pulmon Dis. 2024 Aug 9;19:1835-1848. doi: 10.2147/COPD.S460903. eCollection 2024.
9
Extrafine single inhaler triple therapy effectiveness in COPD patients previously treated with multiple-inhaler triple therapy: the TRIWIN study.既往接受多种吸入器三联疗法治疗的 COPD 患者中超细单吸入器三联疗法的疗效:TRIWIN 研究。
Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241263439. doi: 10.1177/17534666241263439.
10
Comparative effectiveness and safety of triple therapy and non-triple therapy interventions for COPD: an overview of systematic reviews.三联疗法与非三联疗法干预 COPD 的疗效和安全性比较:系统评价概述。
Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241259634. doi: 10.1177/17534666241259634.